anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
Background To support the use of research evidence by community-based organizations the investigators have developed 'Synthesized HIV/AIDS Research Evidence' (SHARE), which is an evidence service for those working in the HIV sector. SHARE consists of several components: 1) an online searchable database of HIV-relevant systematic reviews (retrievable based on a taxonomy of topics related to HIV/AIDS and open text search), 2) periodic email updates, 3) access to user-friendly summaries, and 4) peer relevance assessments. The objective is to evaluate whether this "full serve" evidence service increases the use of research evidence by community-based organizations as compared to a "self-serve" evidence service.

Methods/design The investigators will conduct a two-arm randomized controlled trial (RCT), along with a follow-up qualitative process study to explore the findings in greater depth. All community-based organizations affiliated with Canadian AIDS Society (n=120) will be invited to participate and will be randomized to receive either the "full-serve" version of SHARE or the "self-serve" version (a listing of relevant systematic reviews with links to records on PubMed and worksheets that help community-based organizations find and use research evidence) using a simple randomized design. All management and staff from each organization will be provided access to the version of SHARE that their organization is allocated to. The trial duration will be 10 months (two-month baseline period, six-month intervention period, and two month cross-over period), the primary outcome measure will be the mean number of logins/month/organization (averaged across the number of users from each organization) between baseline and the end of the intervention period and the secondary outcome will be intention to use research evidence as measured by a survey administered to one key decision-maker from each organization. For the qualitative study, one key organizational decision-maker from 15 organizations in each trial arm (n=30) will be purposively sampled. One-on-one semi-structured interviews will be conducted by telephone on their views about and their experiences with the evidence service they received, how helpful it was in their work, why it was helpful (or not helpful), what aspects were most and least helpful and why, and recommendations for next steps.
FIELD: medicine, immunology. SUBSTANCE: invention proposes the preparation that is lyophilized mono-receptor fraction of F(ab) 2 -fragments of equine IgG isolated from fermented equine hyperimmune serum using immunosorbent containing purified concentrated diphtheria anatoxin as ligand. Immunoaffine purification ensures to obtain the preparation with activity of antidiphtheria antibodies 2500 IU/ml, not less, and protein content 3-4%. For preparing the antidiphtheria preparation equine hyperimmune serum is used and for this purpose serum is fermented with pepsin followed by fractionation of proteins with salts and thermal denaturation of inert proteins. Isolation of the end product from fermented hyperimmune serum is performed by specific sorption method. EFFECT: preparing highly purified antidiphtheria preparation with decreased reactivity properties. 3 cl, 3 tbl, 2 dwg
Patients randomised to the comparator group will be treated with Meformin 1g BID and Humulin kwickpen to reach a fP-glucose level of 6 mmol/l. For that reason patients will be instructed to increase the bedtime Insulin dose of 2-4U every third day until this goal is reached.
SUMMARY: After pregnancy, some women experience severe rectus diastasis (RD), with body control dysfunction, midline hernia, or other quality-of-life impairment. The purpose of this study was to describe the authors' experience using hydrodissection and epidural anesthesia for lateral plication modification of abdominoplasty to restore abdominal wall firmness. A total of 46 consecutive patients with RD after pregnancy were enrolled. The mean intraoperative inter-rectus distance was 4.6 cm. RD is not always the only structure that has been elongated. Firmness of the abdominal wall also depends on lateral fascia structures. This study reports the total plicated distance addressing the lateral laxity in the abdominal wall. In this series, total plication was 7.8 cm, and 16 patients had a midline hernia. No hernia recurrences occurred, and the rectus bellies were less than 5 mm apart from each other in all participants, verified with ultrasound after 2 years of follow-up. Patient perspective of care and surgical outcome were recorded. Health-related quality-of-life domains were significantly improved postoperatively. Lumbar back pain visual analogue scale score was 4.5 ± 2.3 preoperatively and 0.5 ± 0.9 postoperatively. The ability to perform sit-ups increased from zero to 11, suggesting better motor control. The total complication rate was 10.9%. Hydrodissection and epidural anesthesia for lateral plication modification offers a reliable and effective treatment method for RD repair with and without a small midline hernia with a low complication rate.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
BACKGROUND: Mastitis is a disease that incurs significant costs in the dairy industry. A promising approach to mitigate its negative effects is to genetically improve the resistance of dairy cattle to mastitis. A meta-analysis of genome-wide association studies (GWAS) across multiple breeds for clinical mastitis (CM) and its indicator trait, somatic cell score (SCS), is a powerful method to identify functional genetic variants that impact mastitis resistance.
RESULTS: We conducted meta-analyses of eight and fourteen GWAS on CM and SCS, respectively, using 30,689 and 119,438 animals from six dairy cattle breeds. Methods for the meta-analyses were selected to properly account for the multi-breed structure of the GWAS data. Our study revealed 58 lead markers that were associated with mastitis incidence, including 16 loci that did not overlap with previously identified quantitative trait loci (QTL), as curated at the Animal QTLdb. Post-GWAS analysis techniques such as gene-based analysis and genomic feature enrichment analysis enabled prioritization of 31 candidate genes and 14 credible candidate causal variants that affect mastitis.
CONCLUSIONS: Our list of candidate genes can help to elucidate the genetic architecture underlying mastitis resistance and provide better tools for the prevention or treatment of mastitis, ultimately contributing to more sustainable animal production.
The invention discloses an application of a lithocarpus polystachyus rehd extract, and a preparation method of the lithocarpus polystachyus rehd extract comprises the following steps: (1) crushing the dried leaves of lithocarpus polystachyus to obtain lithocarpus polystachyus leaf powder; (2) extracting leaf powder of Lithocarpus polystachyus (hook. et hook. F.) Rehd with ethanol under reflux, and recovering ethanol to obtain Lithocarpus polystachyus (hook. et hook. F.) Rehd soft extract; (3) adsorbing the soft extract with D101 macroporous adsorbent resin, sequentially gradient eluting with distilled water, 10% ethanol, 30% ethanol and 50% ethanol, and collecting the eluates; (4) mixing the eluates with 30% ethanol and 50% ethanol, concentrating under reduced pressure, and freeze drying at low temperature to obtain Lithocarpus polystachyus (wall.) Rehd extract. The Lithocarpus polystachyus (Rehd.) Rehd extract has effect of increasing glucagon-like peptide-1, and can be used for preparing food or medicine for increasing glucagon-like peptide-1. The extraction method is simple, easy to operate and more suitable for large-scale industrial production.
PURPOSE:To produce a large amount of LS apoprotein which is an antigen for obtaining a monoclonal antibody useful for the immunological determination of pulmonary surface active substance, by removing lipid from the pulmonary surface active substance separated from the precipitated fraction of the washed liquid of the bronchus and lung of a patient of pulmonary alveolar proteinosis. CONSTITUTION:The objective LS apoprotein composed mainly of proteins having molecular weight of about 62,000 and about 36,000 can be produced by the following procedures. The precipitation fraction of the washed liquid of the lung and/or bronchus of a patient of pulmonary alveolar proteinosis is subjected e.g. to discontinuous sucrose density gradient centrifugation to obtain a pulmonary surface active substance. The substance is dispersed in a solution of a nonionic surfactant (e.g. 5mM tris buffer solution containing 1% polyoxyethylene alkylphenyl ether, 3mM EDTA, 1mM phenylmethylsulfonyl fluoride and 0.5mM dithiosclerotol). Finally, the dispersion is extracted with a butanol/ethanol (6:1) mixture at 0 deg.C to extract and remove lipid.
Chronic Obstructive Pulmonary Disease (COPD) is an umbrella diagnosis defined by obstructive lung function impairments, and is likely to be caused by a multitude of etiologies including environmental exposures, genetic predispositions and developmental factors. Due to the heterogeneity of the disease, molecular and mechanistic sub-phenotyping of COPD represents an essential step to facilitate the development of relevant diagnostic and treatment options for this constantly growing patient group. In the Karolinska COSMIC study, the investigators are investigating molecular sub-phenotypes of smoking-induced COPD. A particular focus relates to recent epidemiological indications of gender differences in both incidence and severity of disease, with post-menopausal women being at greatest risk. The study encompasses profiling of mRNA, miRNA, proteomes, metabolomes and lipid mediators of from multiple lung compartments (airway epithelium, alveolar macrophages, exosomes, and bronchoalveolar exudates) using a range of 'omics platforms, in combination with extensive clinical phenotyping of early stage COPD patients, never-smokers, and smokers with normal lung function from both genders. The primary objective of the study is to identify molecular sub-phenotypes of patients with COPD, specifically by correlating clinical phenotypes multi-molecular 'omics profiling from multiple lung compartments of early stage COPD patients compared to healthy and at-risk control populations. Secondary goals involve identification of subsets of prognostic/diagnostic biomarkers for classification of the defined subgroups, as well as relevant pharmaceutical targets.
BACKGROUND: Arising in the late 1990s, when a promising role in prenatal diagnostics was first delineated for circulating fetal DNA, non-invasive prenatal tests (NIPTs) have been increasingly used with more frequency and popularity. These exams have been used as a prenatal screening tests for genetic diseases. Initially, they were developed for the investigation of the main fetal chromosomal aneuploidies, but lately they have also been used to rule out genomic microrearrangements and monogenic conditions. However, along with great opportunities and potential, the tests can show inconclusive or unexpected results. Several studies have shown that the current pre-test counseling is often insufficient, and more oriented at providing pieces of information about the identifiable diseases rather than providing extensive information on all possible scenarios which may affect both the fetus and the pregnant mother, especially in the case of an invasive test for the pregnant mother.
METHODS AND RESULTS: We have gathered from the literature on NIPT the main pitfalls, imperfections, and particular cases associated with this innovative diagnostic procedure.
CONCLUSIONS: In view of further improvements in the methods that can limit the inconclusive or unexpected results, this paper aims to reinforce the importance of more accurate pre-test counseling with comprehensive information about the above-mentioned questions, as well as ultrasound use and also the creation of an international consensus statement concerning these topics.
The subject invention demonstrates a novel antibacterial activity for 2-phenyl-1,2-benzisoselenazol-3(2H)-one 1-oxide, commonly referred to as ebselen se-oxide, and is directed to the treatment of bacterial infections by administration of an effective amount of said compound. Bacterial infections include those infections which are either systemic or superficial in nature. The treatment is intended for a variety of animals, such as premature neonates to adult humans. Administration of ebselen se-oxide to treat superficial bacterial infections may be performed by a topical application, such as via an ointment, a spray, a cream, a mouth wash, an eye drop solution, an ear drop solution, a soap, a gel, or a lotion. In addition, an antibacterial capsule can be administered orally or intravaginally. Administration of ebselen se-oxide to treat systemic bacterial infections may be performed by an intravenous route, a rectal route, an intranasal route, an oral route, an intramuscular route, or by inhalation. Administration of said compound may also be achieved via aerosol, which can be generated by a nebulizer. Ebselen se-oxide may be administered alone, or with a carrier such as dimethylsulfoxide (DMSO), an alcohol, or other suitable carrier. The effective daily amount of ebselen se-oxide is from about 1 μg/kg to 10 mg/kg of body weight.
The present invention relates to a nanocapsule-structured organic-inorganic nanocomposite allowing treatment and diagnosis simultaneously. The nanocapsule-structured organic-inorganic nanocomposite can be used for a drug delivery system capable of holding a drug in a hollow sphere in a nanocapsule and releasing the drug which has been held by selectively crosslinking a shell, and also can be used even for an MRI contrast medium by including magnetic nanoparticles in the hollow sphere. According to the present invention, the nanocapsule-structured organic-inorganic nanocomposite has the effects of holding a drug or a preferred substance therein and controlling the release time and release rate of the drug which has been held. In addition, the nanocapsule-structured organic-inorganic nanocomposite can be used for a T2 contrast medium by including the magnetic nanoparticles and can be used even for a CT contrast medium by using the characteristics of a substance constituting a nanoshell. In addition, the magnetic nanoparticles generate heat while being defracted when a magnetic field is formed so the nanocapsule-structured organic-inorganic nanocomposite can be used even for a thermal therapeutic agent using the heat. The nanocapsule-structured organic-inorganic nanocomposite has a high X-ray absorption rate according to the substance constituting the nanoshell, thereby being used even for a radiation therapeutic agent. The nanocapsule-structured organic-inorganic nanocomposite generates heat while absorbing the light in a near-infrared region, thereby having an advantage of allowing even a thermal therapy using the heat.
The invention discloses a preparation method of a lidocaine carbonate injection. The preparation method comprises the following processes of solution preparation, pH adjustment, filtration and disinfection. The preparation method is characterized in that the filtration process comprises filtering a solution subjected to pH adjustment by a cellulose acetate microfiltration membrane having an aperture size of 0.22 micrometers, filtering the solution by a PVDF microfiltration membrane having an aperture size of 0.22 micrometers until clarification, filling the filtered solution in an ampoule, and carrying out sealing. The solution subjected to pH adjustment is filtered by the cellulose acetate microfiltration membrane having an aperture size of 0.22 micrometers, then is filtered by the PVDF microfiltration membrane, and is subjected to high-pressure steam sterilization at a high temperature of 121 DEG C so that impurities and bacteria in the solution are removed thoroughly and preparation bioavailability and absorption effects are improved. The preparation method has simple processes and is convenient for operation. The lidocaine carbonate injection obtained by the preparation method is safe and effective in clinical use and has small side-effects. Compared with the existing lidocaine carbonate injection, the lidocaine carbonate injection obtained by the preparation method obviously shortens onset time and pain sensation disappearance time and prolongs anaesthesia duration time.
Receptor-interacting protein kinase 4 (RIPK4) is increasingly recognized as a pivotal player in ovarian cancer, promoting tumorigenesis and disease progression. Despite its significance, the posttranslational modifications dictating RIPK4 stability in ovarian cancer remain largely uncharted. In this study, we first established that RIPK4 levels are markedly higher in metastatic than in primary ovarian cancer tissues through single-cell sequencing. Subsequently, we identified UCHL3 as a key deubiquitinase that regulates RIPK4. We elucidate the mechanism that UCHL3 interacts with and deubiquitinates RIPK4 at the K469 site, removing the K48-linked ubiquitin chain and thus enhancing RIPK4 stabilization. Intriguingly, inhibition of UCHL3 activity using TCID leads to increased RIPK4 ubiquitination and degradation. Furthermore, we discovered that GSK3β-mediated phosphorylation of RIPK4 at Ser420 enhances its interaction with UCHL3, facilitating further deubiquitination and stabilization. Functionally, RIPK4 was found to drive the proliferation and metastasis of ovarian cancer in a UCHL3-dependent manner both in vitro and in vivo. Importantly, positive correlations between RIPK4 and UCHL3 protein expression levels were observed, with both serving as indicators of poor prognosis in ovarian cancer patients. Overall, this study uncovers a novel pathway wherein GSK3β-induced phosphorylation of RIPK4 strengthens its interaction with UCHL3, leading to increased deubiquitination and stabilization of RIPK4, thereby promoting ovarian cancer metastasis. These findings offer new insights into the molecular underpinnings of ovarian cancer and highlight potential therapeutic targets for enhancing antitumor efficacy.
Acute respiratory distress syndrome (ARDS) is defined as a syndrome of acute and persistent lung inflammation with increased vascular permeability and characterized by three clinical features: bilateral radiographic infiltrates; a PaO2/FiO2 ratio of 200 mmHg or less, regardless of the level of PEEP and no clinical evidence for an elevated left atrial pressure. If measured, the pulmonary capillary wedge pressure is 18 mmHg or less. In 1994, the American-European Consensus Conference on acute respiratory distress syndrome (ARDS) issued the above definitions that have been widely used by clinicians and researchers (1, 2) When patients with acute respiratory distress syndrome (ARDS), an age-adjusted incidence of 64 per 100,000 person-years and a mortality of 41 percent were detected. Within intensive care units, approximately ten to 15 percent of admitted patients and up to 20 percent of mechanically ventilated patients meet criteria for ARDS (3-6). The mortality rate varies on the basis of the underlying cause, with most patients dying of multi-organ system failure rather than isolated respiratory insufficiency (5, 7). Large trials suggest that the overall mortality of ARDS ranges from 26 to 58 percent (8, 9). The better outcomes always came from tertiary medical centers or big clinical trials, which somewhat might conceal the fact of presence of higher mortality. The mortality rate in our hospital ever reached or even up to 67.2%(10). To improve the quality of care in ARDS patients still has a long way to. We hope to establish a prospective registration system to understand the real status of quality of care first, and then quality improvement interventions will be followed.
Loss of endothelial integrity and vascular leakage are central features of sepsis pathogenesis; however, no effective therapeutic mechanisms for preserving endothelial integrity are available. Here we show that, compared to dermal microvessels, brain microvessels resist infection by Neisseria meningitidis, a bacterial pathogen that causes sepsis and meningitis. By comparing the transcriptional responses to infection in dermal and brain endothelial cells, we identified angiopoietin-like 4 as a key factor produced by the brain endothelium that preserves blood-brain barrier integrity during bacterial sepsis. Conversely, angiopoietin-like 4 is produced at lower levels in the peripheral endothelium. Treatment with recombinant angiopoietin-like 4 reduced vascular leakage, organ failure and death in mouse models of lethal sepsis and N. meningitidis infection. Protection was conferred by a previously uncharacterized domain of angiopoietin-like 4, through binding to the heparan proteoglycan, syndecan-4. These findings reveal a potential strategy to prevent endothelial dysfunction and improve outcomes in patients with sepsis.
* To minimize the radiation absorbed dose to the bladder, encourage adequate hydration. Encourage the patient to drink water or other fluids (as tolerated) in the 4 hours before their PET study.
  * Encourage the patient to void as soon as the imaging study is completed and as often as possible thereafter for at least one hour.
  * Screen patients for clinically significant blood glucose abnormalities by obtaining a history and/or laboratory tests [see Warnings and Precautions ( 5.2)]. Prior to Fludeoxyglucose F 18 PET imaging in the oncology and neurology settings, instruct patient to fast for 4 - 6 hours prior to the drug's injection. 
  * In the cardiology setting, administration of glucose-containing food or liquids (e.g., 50 - 75 grams) prior to Fludeoxyglucose F 18 Injection facilitates localization of cardiac ischemia.
Vaniprevir 600 mg and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
Participants will receive the diet and exercise content simultaneously in combined web-based sessions. Participants will receive and participate in web-based sessions that focus on diet and exercise for 12 months. Participants will be encouraged to track their diet, weight and physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).